Cellerant Therapeutics is a clinical-stage company developing innovative cell- and antibody-based immunotherapies for hematologic malignancies and other blood-related disorders. Cellerant’s romyelocel-L is a universal cell therapy which does not require HLA matching intended to prevent bacterial and fungal infections during neutropenia. In a randomized, controlled Phase 2 clinical trial in AML patients, romyelocel-L reduced infections and days in hospital. Cellerant is developing two novel antibody drug-conjugate (ADC) products: CLT030 to treat AML by selectively targeting and killing leukemic stem and blast cells, and CSC012-ADC for hematologic malignancies and solid tumor indications.
Company Details
- Employees
- 17
- Founded
- -
- Address
- 1561 Industrial Rd, San Carlos,california 94070,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.cellerant.com
- HQ
- San Carlos, California
Cellerant Therapeutics Questions
Cellerant Therapeutics's website is http://www.cellerant.com
Cellerant Therapeutics's LinkedIn profile is https://www.linkedin.com/company/cellerant-therapeutics-inc
Cellerant Therapeutics has
17 employees.
View email and phone details for 17
employees at Cellerant Therapeutics.
Cellerant Therapeutics's industry is
Biotechnology Research
Cellerant Therapeutics's top competitors are
Vir Biotechnology, Inc.,
Igm Biosciences, Inc.,
Aarvik Therapeutics Inc,
Cargo Therapeutics,
Citra Bioconsulting,
Genentech,
Adverum Biotechnologies,
Modmab Therapeutics,
Arsenal Biosciences, Inc.,
Chief.
Cellerant Therapeutics's categories are Biotechnology Research
Cellerant Therapeutics's founding year is 2003
